Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EMERGE-201: A Phase 2, Multicenter, Open-label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced or Metastatic Solid Tumors

NCT05126433 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT05126433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05126433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EMERGE-201: A Phase 2, Multicenter, Open-label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced or Metastatic Solid Tumors
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
March 3, 2022
Completion date
December 20, 2023
Enrollment
47 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, homologous recombination deficient-positive malignancies agnostic, metastatic solid tumor, poorly differentiated neuroendocrine carcinomas, urothelial cancer